Synthetic gene circuits moving into the clinic

References

[1] Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., (2018) Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol., 36, 857–864

[2] Esensten, J. H., Bluestone, J. A. and Lim, W. A. (2017) Engineering therapeutic T cells: from synthetic biology to clinical trials. Annu. Rev. Pathol., 12, 305–330

[3] Tigges, M., Marquez-Lago, T. T., Stelling, J. and Fussenegger, M. (2009) A tunable synthetic mammalian oscillator. Nature, 457, 309–312

[4] Gardner, T. S., Cantor, C. R. and Collins, J. J. (2000) Construction of a genetic toggle switch in Escherichia coli. Nature, 403, 339–342

[5] Friedland, A. E., Lu, T. K., Wang, X., Shi, D., Church, G. and Collins, J. J. (2009) Synthetic gene networks that count. Science, 324, 1199–1202

[6] Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R. and Benenson, Y. (2011) Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science, 333, 1307–1311

[7] Huang, H., Liu, Y., Liao, W., Cao, Y., Liu, Q., Guo, Y., Lu, Y. and Xie, Z. (2019) Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat. Commun., 10, 4801

[8] Nissim, L., Wu, M. R., Pery, E., Binder-Nissim, A., Suzuki, H. I., Stupp, D., Wehrspaun, C., Tabach, Y., Sharp, P. A. and Lu, T. K. (2017) Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy. Cell, 171, 1138–1150.e15

[9] Williams, J. Z., Allen, G. M., Shah, D., Sterin, I. S., Kim, K. H., Garcia, V. P., Shavey, G. E., Yu, W., Puig-Saus, C., Tsoi, J., (2020) Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science, 370, 1099–1104

[10] Kemmer, C., Gitzinger, M., Daoud-El Baba, M., Djonov, V., Stelling, J. and Fussenegger, M. (2010) Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat. Biotechnol., 28, 355–360

[11] Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. and Lim, W. A. (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science, 350, aab4077

[12] Yin, J., Yang, L., Mou, L., Dong, K., Jiang, J., Xue, S., Xu, Y., Wang, X., Lu, Y. and Ye, H. (2019) A green tea-triggered genetic control system for treating diabetes in mice and monkeys. Sci. Transl. Med., 11, eaav8826

[13] Ye, H., Xie, M., Xue, S., Charpin-El Hamri, G., Yin, J., Zulewski, H., & Fussenegger, M. (2017) Self-adjusting synthetic gene circuit for correcting insulin resistance. Nat. Biomed. Eng., 1, 0005

[14] Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J. R., James, M. J., Abin-Fuentes, A., (2020) Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat. Commun., 11, 2739

[15] Kitada, T., DiAndreth, B., Teague, B. and Weiss, R. (2018) Programming gene and engineered-cell therapies with synthetic biology. Science, 359, eaad1067

COMPLIANCE WITH ETHICS GUIDELINES

Zhen Xie and Huiya Huang have filed patent applications on part of work discussed in this article. Zhen Xie is a co-founder of SyngenTech. Huiya Huang owns stock in SyngenTech.

RIGHTS & PERMISSIONS

2021 Higher Education Press